Overview

A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection

Status:
Completed
Trial end date:
2017-05-23
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study that will investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in combination with oseltamivir versus a comparator arm of placebo with oseltamivir.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Oseltamivir